Zydus Cadila gets USFDA’s final nod for fungal treatment drug

Drug firm ZydusCadila has received final approval from the US health regulator to market Voriconazole tablets, used to treat fungal infections, in the American market.The ZydusCadila has received final approval from the US Food and Drug Administration (USFDA) to market Voriconazole tablets in strengths of 50 and 200 mg, CadilaHealhtcare said in a BSE filing.

The drug will be produced at the groups formulations manufacturing facility at Baddi (Himachal Pradesh).

Citing IMS data, the company said the estimated sales for Voriconazole tablets is USD 92.8 million as on March 2016.

Related Posts

Jaipur Jail Nursing Officer Busted for Supplying Narcotics to Inmates

Jaipur: A Grade Second nursing officer at Jaipur Central Jail has been arrested for allegedly supplying narcotic drugs to prisoners, following a tip-off from an inmate and a trail of…

17760 banned capsules caught during checking, accused arrested

Bijnor/Rehad:  Late Friday evening, a joint team of drug inspector and police seized 17760 banned capsules during checking. The police have also arrested the accused. The drug inspector and police…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Health dept cracks down on ‘Sojat’ henna fraud by pvt cos

Health dept cracks down on ‘Sojat’ henna fraud by pvt cos

BDMAI’s e-marketing portal to promote Indian pharma products and services

BDMAI’s e-marketing portal to promote Indian pharma products and services

FIR against pharma dealer for supplying dubious snake antidote to govt

FIR against pharma dealer for supplying dubious snake antidote to govt

Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

One arrested in spurious rabies vaccine racket: Govt tells RS

One arrested in spurious rabies vaccine racket: Govt tells RS

Drug testing lab at Baddi under lens over chronic delays, missed deadlines

Drug testing lab at Baddi under lens over chronic delays, missed deadlines